| Clinical Study of GanKang II on Hepatic Fibrosis in Chronic Hepatitis B Objective:To investigate the clinical effect of GanKang II on Hepatic Fibrosis in Chronic Hepatitis B. Methods:Data of 65 patients with hepatic fibrosis in chronic hepatitis B were collected in people's hospital of Shi Yan city, Hu Bei province during the period from 2003.02 to 2005.02. These patients were dⅣided randomly into one treatment-group and one contrast-group. In treatment-group, there were 33 patients, male: 23, female: 10; age range: 18-64 years old; average of age: 35.2+9.6; duration of desease: 0.5~20years; middle extent: 22, high extent: 11. In contrast-group, there were 32 patients, male: 22, female: 10; age range: 18-63 years old; age average: 34.0±9.2; duration of desease: 0.5~20 years; middle extent: 21, high extent: 11. Treatment-group was treated with GanKangⅡ 150ml, twice a day and contrast-group was treated with DaHuangZheChongWan (3.0g/times, twice a day). In the same time, all patients were treated with regular medicine, for example: NengLiang,Oleanolic-Acid, Vitamin, etc. We observed clinical symptoms and physical signs, serological indexes, results of biochemical analysis, B-type ultrasonic diagnosis, hepatic tissue pathology pre and after treatment. Clinical symptoms are lacking strength, pain of rib, inappetence, expanding of abdomen, weakness of waist and knee, dryness of mouth. Physical signs are hepatic countenance, hepatic palm, spider naevus, signs of tongue, signs of pulse. Hepatic function indexes are ALT, AST, TBIL, A, G. The serum fibrosis makers are hyaluronic acid (HA), procollagen Ⅲ (PCⅢ), collagen Ⅳ (Ⅳ-C), Laminin (LN). Hepatic viral makers are HbsAg, HBeAg, HBV-DNA. B-type ultrasonic examination indexes are length of hepatic right oblique pathway, wideness of portal vein, thickness of spleen vein, thickness of spleen. The grade of inflammation and stage of fibrosis were assessed by means of pathological observation. Results:(1) Clinical symptoms and physical signs were improved markedly in treatment-group. Among these, lacking strength, pain of rib, inappetence, expanding of abdomen, weakness of waist and knee, dryness of mouth, signs of tongue, signs of pulse were improved significantly (P<0.05). There were significant differences between treament-group and contrast-group regarding lacking strength, inappetence and expanding of abdomen.(2) The level of the serums ALT, AST and TBIL decreased significantly (p<0.01); the level of serum GLB decreased (p<0.05); the level of serum ALB increased (p<0.05) pre and after treament in treatment-group. There were significant differences between treatment-group and contrast-group on ALT, AST and TBIL (P<0.01); GLB (P<0.05). But there was no difference between treatment-group and contrast-group regarding ALB (P>0.05).(3) The level of the serums HA, LN, PCⅢ and CIV decreased significantly (p<0.01). PCⅢ decreased (p<0.01). There were significant differences between treatment-groupand contrast-group on HA (P>0.01), LN and Ⅳ-C (P<0.05). There was no difference between treatment-group and contrast-group on PCⅢ (P>0.05).(4) After treatment, the clearance rate of HbeAg and HBV-DNA, as well as the variation of HbeAb, improved, respectively reaching 30.43%, 38.46% and 21.74%.(5) B-type ultrasonic examination indexes were improved as regards length of hepatic right oblique pathway, wideness of portal vein, thickness of spleen vein and thickness of spleen.(6) After treatment, the grade of inflammation and stage of fibrosis were improved. These indicate GanKang Ⅱ possesses functions of attenuating inflammation, stopping or reversing fibrogenesis.Conclusion:(1) GanKang Ⅱ is effective in improving clinical symptoms, physical signs, serological indexes, viral indexes, hepatic fibrosis indexes, B-type ultrasonic examination indexes, etc... The grade of inflammation and stage of fibrosis were improved.(2) GanKang Ⅱ possesses functions of protecting hepatic cells, lowering enzymes, resisting oxygenation, resisting inflammation... |
PDF Full Text Request